Atria Wealth Solutions Inc. Purchases 1,205 Shares of Sanofi (NASDAQ:SNY)

Atria Wealth Solutions Inc. lifted its position in shares of Sanofi (NASDAQ:SNY) by 7.9% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 16,370 shares of the company’s stock after purchasing an additional 1,205 shares during the period. Atria Wealth Solutions Inc.’s holdings in Sanofi were worth $814,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Commonwealth Equity Services LLC raised its position in shares of Sanofi by 6.2% during the third quarter. Commonwealth Equity Services LLC now owns 173,643 shares of the company’s stock worth $9,314,000 after acquiring an additional 10,185 shares during the last quarter. Cambridge Investment Research Advisors Inc. boosted its stake in shares of Sanofi by 16.0% in the 3rd quarter. Cambridge Investment Research Advisors Inc. now owns 39,657 shares of the company’s stock valued at $2,127,000 after purchasing an additional 5,457 shares during the last quarter. Raymond James Financial Services Advisors Inc. increased its position in shares of Sanofi by 30.1% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 220,026 shares of the company’s stock worth $11,802,000 after buying an additional 50,882 shares during the period. Stratos Wealth Partners LTD. raised its stake in Sanofi by 15.2% during the third quarter. Stratos Wealth Partners LTD. now owns 6,389 shares of the company’s stock worth $343,000 after buying an additional 845 shares during the last quarter. Finally, Lindbrook Capital LLC lifted its holdings in Sanofi by 28.3% in the third quarter. Lindbrook Capital LLC now owns 5,157 shares of the company’s stock valued at $277,000 after buying an additional 1,136 shares during the period. Institutional investors and hedge funds own 10.04% of the company’s stock.

Sanofi Stock Performance

Shares of Sanofi stock opened at $49.01 on Friday. The business has a 50-day simple moving average of $47.89 and a 200 day simple moving average of $48.27. The firm has a market capitalization of $123.98 billion, a price-to-earnings ratio of 24.63, a PEG ratio of 1.38 and a beta of 0.61. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.87. Sanofi has a one year low of $42.63 and a one year high of $55.93.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $0.89 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). Sanofi had a net margin of 10.52% and a return on equity of 19.69%. The business had revenue of $11.76 billion for the quarter, compared to analyst estimates of $13.02 billion. On average, research analysts anticipate that Sanofi will post 4.12 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be issued a dividend of $1.478 per share. This is a positive change from Sanofi’s previous annual dividend of $1.38. This represents a yield of 2.98%. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s payout ratio is currently 69.35%.

Analyst Ratings Changes

SNY has been the subject of several research analyst reports. Morgan Stanley started coverage on Sanofi in a research report on Tuesday, January 23rd. They issued an “equal weight” rating and a $55.00 price objective for the company. StockNews.com lowered Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. Finally, TheStreet downgraded shares of Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, Sanofi has a consensus rating of “Moderate Buy” and an average price target of $55.00.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.